Vir Biotechnology Current Ratio 2018-2021 | VIR

Current and historical current ratio for Vir Biotechnology (VIR) from 2018 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Vir Biotechnology current ratio for the three months ending June 30, 2021 was 5.91.
Vir Biotechnology Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.86B $0.15B 5.91
2021-03-31 $0.99B $0.36B 2.75
2020-12-31 $0.77B $0.10B 7.80
2020-09-30 $0.85B $0.08B 11.03
2020-06-30 $0.58B $0.06B 10.53
2020-03-31 $0.38B $0.06B 6.69
2019-12-31 $0.40B $0.06B 6.81
2019-09-30 $0.34B $0.04B 7.62
2019-06-30 $0.00B 0.00
2019-03-31 $0.00B 0.00
2018-12-31 $0.00B 0.00
2018-09-30 $0.00B 0.00
2017-12-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $5.262B $0.076B
Vir Biotechnology Inc. is a clinical-stage immunology company. It is focused on combining immunologic insights to treat and prevent serious infectious diseases. The company's development pipeline consists of product candidates targeting the hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis. Vir Biotechnology Inc. is based in San Francisco, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86